title: [Prognostic factor of primary liver cancer treated by hypofractionated three-dimensional conformal radiotherapy].
abstract: OBJECTIVE
  To evaluate the toxicity and efficacy of primary liver cancer (PLC) treated by hypofractionated three-dimensional conformal radiotherapy (3DCRT) and investigate the prognostic factors.
  
  
  METHODS
  Between April 1999 and August 2003, 128 PLC patients received hypofractionated 3DCRT. According to UICC/AJCC staging system, there were 83 T3 patients, 45 T4, with none of them having lymph node metastasis. The mean value of gross tumor volume (GTV) was (458.92 +/- 429.8) cm(3) (6.2-2097 cm(3)). Thirty-four patients had portal vein tumor thrombosis (PVTT). 108 patients had Child-Pugh Grade A liver cirrhosis and 20 Child-Pugh Grade B liver cirrhosis. All patients received a total dose of (53.6 +/- 6.6) Gy/4-8 Gy per fraction/3 fractions per week. Forty-eight of these patients received 3DCRT combined with transarterial chemoembolization (TACE).
  
  
  RESULTS
  Seven patients died within 3 months after the treatment were dismissed from the series. The response rate (CR + PR) was 55% (67/121). The overall 1-, 2-, and 3-year survival rate was 65.0%, 43.3%, and 33.1%, respectively. T stage (P = 0.001), GTV (P = 0.0001), PVTT (P = 0.0001) and Child-Pugh Grade (P = 0.0001) had significant impact on the overall survival. However, only GTV and Child-Pugh Grade were independent significant prognostic factors by Cox-regression analysis, (P = 0.044 and P = 0.015).
  
  
  CONCLUSIONS
  T stage, GTV, PVTT and Child-Pugh Grade have significant impact on the overall survival in primary liver cancer patients treated by three-dimensional conformal radiotherapy. But only GTV and Child-Pugh Grade are independent prognostic factors.
authors.affiliation: Cancer Hospital, Guangxi Medical University, Nanning 530021, China. shixliang@sina.com.cn
authors.forename: Shi-xiong
authors.initials: SX
authors.lastname: Liang
authors.forename: Guo-liang
authors.initials: GL
authors.lastname: Jiang
authors.forename: Xiao-dong
authors.initials: XD
authors.lastname: Zhu
authors.forename: Xiao-long
authors.initials: XL
authors.lastname: Fu
authors.forename: Fu-xiang
authors.initials: FX
authors.lastname: Li
authors.forename: Qi-fang
authors.initials: QF
authors.lastname: Huang
authors.forename: An-yu
authors.initials: AY
authors.lastname: Wang
authors.forename: Long
authors.initials: L
authors.lastname: Chen
authors.forename: Hai-jie
authors.initials: HJ
authors.lastname: Lu
mesh_terms: D000328:Adult; D000368:Aged; D006528:Carcinoma, Hepatocellular / Q000532:radiotherapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D021621:Imaging, Three-Dimensional; D008113:Liver Neoplasms / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011880:Radiotherapy Planning, Computer-Assisted; D020266:Radiotherapy, Conformal / Q000379:methods*; D012044:Regression Analysis; D012189:Retrospective Studies